TLC Seeks A Second Opinion On Doxolipad

 
• By Dave Wallace

After the CHMP previously refused to recommend granting approval for TLC’s doxorubicin hybrid, the firm has asked the committee within the EMA to revisit its opinion.

EMA
The EMA’s CHMP Has Been Asked To Look Again At TLC’s Doxorubicin Hybrid • Source: Shutterstock

More from Regulation

More from Policy & Regulation